Skip to main content
Infilbray™ (venglustat) logo
A young boy playing a keyboard overlayed with purple light
A young boy playing a keyboard overlayed with purple light

What is the dosing and administration for Infilbray™ (venglustat)?

Infilbray is approved to treat the neurologic manifestations of Gaucher disease type 3 in patients who weigh 15 kg or more1

What you’ll learn on this page:

  • Infilbray for Gaucher disease type 3 is administered with dosing in a once-daily oral tablet1
  • Infilbray for Gaucher disease type 3 is available in 6 mg and 15 mg tablets1
  • Dosing for Infilbray is based on age and weight1:
    • Adults (≥18 years): 15 mg orally, once daily
    • Pediatric patients (≥15 kg): weight-based dosing (see dosing table below)
  • Infilbray tablets are stored at room temperature, in the original package to protect from moisture, and should be kept in the original package until immediately before administration1

Infilbray is the first and only oral, once-daily therapy in Gaucher disease type 3 that is active in the CNS1

Line icon of a brain

Can be initiated in appropriate patients as soon as they are diagnosed with GD3.

Icon of a female doctor with a stethoscope around her neck

Infilbray should be initiated and supervised by a physician knowledgeable in the management of Gaucher disease type 3.

Purple text reading “1x Daily”

Infilbray is available in 6 mg and 15 mg tablets taken once daily.

Important recommendations for prior to and during Infilbray treatment1 

Prior to treatment initiation:


  • Assess patients’ underlying risk of psychiatric disorders
  • Perform an ophthalmologic examination in pediatric patients
  • Verify pregnancy status in females of reproductive potential


Consider Infilbray warnings and precautions1 

Suicidal ideation and behavior    
Suicidal ideation and behavior have been reported in patients with Gaucher disease type 3 receiving Infilbray and in unapproved populations receiving another oral formulation of venglustat, both with and without a history of psychiatric disorders.

Assess patients’ underlying risk of psychiatric disorders prior to treatment initiation and monitor for depressive symptoms or suicidal thoughts during treatment with Infilbray. Use caution when prescribing Infilbray to patients with a history of psychiatric disorders. Inform patients or caregivers of the potential for behavioral and mood changes and encourage them to seek medical attention for manifestations of suicidal ideation and behavior, new onset or worsening depression, or other mood changes. Consider changing the therapeutic regimen, including possibly discontinuing Infilbray, if such events occur.


Lens opacification in pediatric patients    
Lens opacification may occur in pediatric patients treated with Infilbray. In pediatric patients, perform an ophthalmological assessment prior to initiation and annually during treatment. Advise pediatric patients and caregivers to report any visual disturbances during treatment.


Embryofetal toxicity    
Based on findings from animal studies, Infilbray may cause fetal harm when administered to a pregnant woman. Prior to initiation, verify pregnancy status in females of reproductive potential and advise them of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment and for 11 days after the last dose. 

Infilbray can be taken orally with or without food1

Patients can swallow the tablet(s) whole, or chew the tablet(s) first and then swallow. Alternatively, patients can crush and mix Infilbray tablets with liquids or soft foods if they take Infilbray within 30 minutes after mixing. Patients should not mix Infilbray with juice containing grapefruit or Seville oranges.

Infilbray offers age- and weight-based dosing1

Age

Body weight

Recommended dosage

18 years and older

—

15 mg orally once daily

6 to less than 18 years of age

50 kg and above

15 to less than 50 kg

2 x 6 mg orally once daily

Less than 6 years of age

30 to less than 50 kg

15 to less than 30 kg

6 mg orally once daily

Missed or vomited dose1

If a dose is missed by more than 12 hours, skip the missed dose and take the next dose at the regularly scheduled time.

 Do not double the next scheduled dose.

If vomiting occurs after taking a dose of Infilbray, do not take an additional dose. Take the next dose at the regularly scheduled time. Do not double the next scheduled dose.

Administration in specific populations1

Dosage modifications for patients receiving strong CYP3A inhibitors

Avoid concomitant use of Infilbray with strong CYP3A inhibitors.

If concomitant use is unavoidable, reduce the Infilbray dosage as follows:

  • Adults: 2 x 6 mg orally once daily
  • Pediatric patients 6 to less than 18 years of age
    • 50 kg and above: 2 x 6 mg orally once daily
    • 15 kg to less than 50 kg: 6 mg orally once daily
  • Pediatric patients less than 6 years of age
    • 30 kg to less than 50 kg: 6 mg orally once daily
    • 15 kg to less than 30 kg: 6 mg orally, every other day
Inform patients to avoid consumption of grapefruit or Seville oranges during treatment with Infilbray.

Recommended dosage of Infilbray for adult patients with renal impairment

eGFR

Recommended dosage

≥30 mL/min

15 mg orally once daily

<30 mL/min (severe renal impairment)

2 x 6 mg orally once daily

Recommended dosage of Infilbray for pediatric patients with renal impairment weighing ≥15 kg

eGFR

Recommended dosage

≥30 mL/min/1.73 m2

No modification

<30 mL/min/1.73 m2

No data available to establish dosing recommendation

Infilbray is a tablet medication stored at room temperature1

  • Infilbray tablets are available in two strengths: 6 mg and 15 mg
  • Infilbray tablets are packaged in blister cards and supplied in child-resistant cartons. Each carton contains 1 blister card of 28 
tablets
  • The 6 mg tablets are white to off-white, oblong, apricot-flavored, and debossed with a “6” on one side 
  • The 15 mg tablets are white to off-white, round, apricot-flavored, and debossed with a “15” on one side
  • Infilbray tablets should be stored at temperatures ranging from 20 °C to 25 °C (68 °F to 77 °F) with excursions permitted 
between 15 °C and 30 °C (59 °F and 86 °F). See United States Pharmacopeia Controlled Room Temperature
  • Store in the original package to protect from moisture
  • Keep in original package until immediately before administration

Infilbray offers age- and weight-based dosing that is conveniently administered as a once-dailyoral tablet stored at room temperature.1

Frequently asked questions

Definitions: CNS=central nervous system; eGFR=estimated glomerular filtration rate; ERT=enzyme replacement therapy; GCSi=glucosylceramide synthase inhibitor; GD3=Gaucher disease type 3; GL-1=glucosylceramide; IV=intravenous; lyso-GL-1=glucosylsphingosine.

Relevant pages to view:

Indication

INFILBRAY (venglustat) is indicated for the treatment of neurological manifestations of Type 3 Gaucher disease (GD3) in patients weighing at least 15 kg. 

Important Safety Information

Warnings and Precautions:
Suicidal Ideation and Behavior:

Suicidal ideation and behavior have been reported in patients with GD3 receiving INFILBRAY and in unapproved populations receiving another formulation of venglustat, both with and without a history of psychiatric disorders. Assess patients' underlying risk of psychiatric disorders prior to initiation and monitor for depressive symptoms or suicidal thoughts during treatment. Use caution when prescribing to patients with a history of psychiatric disorders. Inform patients or caregivers of the potential for behavioral and mood changes and to seek medical attention for manifestations of suicidal ideation and behavior, new onset or worsening depression, or other mood changes. Consider changing the therapeutic regimen, including possibly discontinuing INFILBRAY, if such events occur.

Lens Opacification in Pediatric Patients:

Lens opacification may occur in pediatric patients treated with INFILBRAY. In pediatric patients, perform ophthalmological assessment prior to initiation and annually during treatment. Advise pediatric patients and caregivers to report any visual disturbances during treatment.

Embryofetal Toxicity:

Based on animal studies, INFILBRAY may cause fetal harm when administered to a pregnant woman. Prior to initiation, verify pregnancy status in females of reproductive potential and advise them of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment and for 11 days after the last dose.

Adverse Reactions:
The most common adverse reactions reported in ≥10% of INFILBRAY-treated GD3 patients aged ≥12 years were diarrhea, splenomegaly, nausea, depression, gastroenteritis, and vomiting.


Drug Interactions:
Strong CYP3A Inhibitors: Avoid concomitant use with INFILBRAY. Strong CYP3A inhibitors increase venglustat exposure, which may increase the risk of adverse reactions. If concomitant use is unavoidable, reduce INFILBRAY dosage.

Strong or Moderate CYP3A Inducers: Avoid concomitant use with INFILBRAY. Strong or moderate CYP3A inducers decrease venglustat exposure, which may result in decreased efficacy. If concomitant use is unavoidable, monitor for reduced effectiveness.

Please see Full Prescribing Information for INFILBRAY.

Indication

Important Safety Information

References: 1. Infilbray (venglustat). Prescribing information. Genzyme Corporation, Cambridge, MA. 2. Cerezyme (imiglucerase). Prescribing information. Genzyme Corporation, Cambridge, MA.

©2026 Sanofi. All rights reserved. All trademarks mentioned are the property of the Sanofi group. MAT-US-2608189-v1.0-11/2026. Last updated: November 2026.